EpiCypher™ Introduces Nucleosome Product Line Complete product line of nucleosomes allows researchers to identify authentic hits on a more consistent basis

Research Triangle Park, N.C. –July 9, 2015 – EpiCypher today announced the introduction of a complete line of purified and fully recombinant nucleosomes for use in epigenetic and chromatin biology research. Nucleosomes are the most physiologically relevant substrates for chromatin modifying enzymes and are ideal for protein binding and inhibitor screening assays in drug discovery research. EpiCypher leads the industry in both innovation and quality of nucleosome-based products.

The most compelling feature of nucleosomes from EpiCypher is the superior purity of the product (>98%), allowing more focus on optimizing libraries and reaching successful hits on a more consistent basis. “EpiCypher offers the highest quality and most highly validated nucleosome products currently available. Epigenetic proteins and enzymes are becoming increasingly important targets for therapeutic intervention. The incorporation of EpiCypher’s nucleosomes into drug development research allows researchers to identify authentic hits on a more consistent basis, as well as reducing the amount of substrate required,” states EpiCypher President Jim Bone. The stringent quality control standards utilized by EpiCypher ensure reliable and repeatable results every time, negligible lot-to-lot variation and a reduced risk of false positives or false negatives.

About EpiCypher Pioneering the Science of Epigenetics™ A pioneer in the field of epigenetics and chromatin biology, EpiCypher is a bioscience company developing transformative technologies and delivering superior products to researchers worldwide.

EpiCypher’s patented EpiTitan™ Histone Peptide Array is the most advanced histone array currently available. EpiCypher also sells nucleosomes, recombinant histone binding proteins, peptides and antibodies, as well as peptide synthesis and peptide array screening services. For more information about EpiCypher, visit epicypher.com.

Media Contact: Leslie Lewis, EpiCypher, Inc. [email protected]